​

CorMedix (CRMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRMD Stock Forecast

CorMedix (CRMD) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $13.75, with a high of $16.00 and a low of $13.00. This represents a 110.24% increase from the last price of $6.54.

- $4 $8 $12 $16 $20 High: $16 Avg: $13.75 Low: $13 Last Closed Price: $6.54

CRMD Stock Rating

CorMedix stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

CRMD Price Target Upside V Benchmarks

TypeNameUpside
StockCorMedix110.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts146
Avg Price Target$13.00$13.75$15.67
Last Closing Price$6.54$6.54$6.54
Upside/Downside98.78%110.24%139.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2634---7
Feb, 2634---7
Jan, 2634---7
Dec, 2534---7
Nov, 2543---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2026Roanna RuizLeerink Partners$13.00$6.46101.24%98.78%
Jan 23, 2026H.C. Wainwright$13.00$7.4474.73%98.78%
Jan 21, 2026RBC Capital$13.00$6.8888.95%98.78%
Jan 08, 2026Truist Financial$16.00$7.44115.05%144.65%
Oct 21, 2025Gregory RenzaRBC Capital$22.00$12.1680.92%236.39%
Aug 08, 2025Brandon FolkesH.C. Wainwright$17.00$10.3364.57%159.94%
Mar 13, 2024Gregory RenzaRBC Capital$9.00$3.90130.77%37.61%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2026Leerink PartnersOutperformOutperformhold
Oct 21, 2025RBC CapitalOutperformOutperformhold
Aug 08, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024RBC CapitalOutperformOutperformhold
Aug 26, 2024Rodman & RenshawBuyinitialise
Aug 10, 2023RBC CapitalOutperforminitialise
Apr 25, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.75$-0.74$-0.91$-0.30$2.25---
Avg Forecast$-0.80$-0.73$-0.85$-0.41$0.50$0.98$1.81$2.68
High Forecast$-0.68$-0.72$-0.78$-0.38$0.59$1.33$2.56$3.18
Low Forecast$-0.91$-0.75$-1.01$-0.49$0.46$0.74$0.99$2.46
Surprise %-6.25%1.37%7.06%-26.83%350.00%---

Revenue Forecast

$-50M $40M $130M $220M $310M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$190.94K$65.41K-$43.47M$311.71M---
Avg Forecast$124.33K$26.23K$-333.33K$39.55M$126.15M$161.46M$238.61M$330.20M
High Forecast$138.22K$26.63K$-312.64K$45.29M$144.46M$162.55M$240.51M$378.14M
Low Forecast$110.66K$25.94K$-381.72K$37.09M$118.32M$160.37M$236.71M$309.70M
Surprise %53.57%149.33%-9.92%147.09%---

Net Income Forecast

$-100M $-40M $20M $80M $140M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.21M$-29.70M$-46.34M$-17.93M$163.06M---
Avg Forecast$-40.55M$-37.19M$-46.34M$-22.00M$26.74M$52.56M$90.20M$136.17M
High Forecast$-34.76M$-36.66M$-39.77M$-19.19M$30.15M$67.68M$130.16M$161.86M
Low Forecast$-46.44M$-37.93M$-51.42M$-24.81M$23.32M$37.44M$50.25M$125.18M
Surprise %-30.44%-20.14%--18.49%509.86%---

CRMD Forecast FAQ

Is CorMedix stock a buy?

CorMedix stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CorMedix is a favorable investment for most analysts.

What is CorMedix's price target?

CorMedix's price target, set by 6 Wall Street analysts, averages $13.75 over the next 12 months. The price target range spans from $13 at the low end to $16 at the high end, suggesting a potential 110.24% change from the previous closing price of $6.54.

How does CorMedix stock forecast compare to its benchmarks?

CorMedix's stock forecast shows a 110.24% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CorMedix over the past three months?

  • March 2026: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CorMedix’s EPS forecast?

CorMedix's average annual EPS forecast for its fiscal year ending in December 2026 is $0.98, marking a -56.44% decrease from the reported $2.25 in 2025. Estimates for the following years are $1.81 in 2027, and $2.68 in 2028.

What is CorMedix’s revenue forecast?

CorMedix's average annual revenue forecast for its fiscal year ending in December 2026 is $161.46M, reflecting a -48.20% decrease from the reported $311.71M in 2025. The forecast for 2027 is $238.61M, and $330.2M for 2028.

What is CorMedix’s net income forecast?

CorMedix's net income forecast for the fiscal year ending in December 2026 stands at $52.56M, representing a -67.77% decrease from the reported $163.06M in 2025. Projections indicate $90.2M in 2027, and $136.17M in 2028.